Kite Pharma

February 11, 2020February 11, 2020

FDA Grants Priority Review to Kite’s CAR T-cell Therapy KTE-X19 for Mantle Cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review Kite Pharma’s application requesting the approval of its investigational CAR T-cell therapy KTE-X19 for treating adult patients with relapsed or ... Read more

February 4, 2020February 4, 2020

CAR T-cell Therapy KTE-X19 Under Review in Europe and US for Mantle Cell Lymphoma

News

The European Medicines Agency (EMA) has validated and is now reviewing Kite Pharma’s application requesting the approval of its investigational chimeric antigen receptor (CAR) T-cell therapy KTE-X19 for adult patients with relapsed or ... Read more

October 1, 2019October 1, 2019

Radiation Prior to CAR T-cell Therapy in Non-Hodgkin’s Lymphoma May Ease Side Effects, Study Suggests

News

Treating non-Hodgkin’s lymphoma patients with radiation before giving them CAR T-cell therapy may lessen the likelihood of them experiencing toxic side effects, a small study suggests. This finding was detailed at the ... Read more

February 26, 2019

Yescarta Approved in Canada for Adults with Relapsed or Refractory Large B-cell Lymphoma

News

Health Canada has approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with diffuse large B-cell lymphoma (DLBCL) who have already received two or more lines of systemic therapy. Specifically, ... Read more

December 12, 2018

Follow-up Trial Results Reinforce Yescarta as Relapsed Non-Hodgkin’s Lymphoma Therapy

News

More than two years after receiving treatment with Yescarta (axicabtagene ciloleucel), 51% of non-Hodgkin’s lymphoma patients included in the ZUMA-1 Phase 1/2 clinical trial are still alive, and 39% are ... Read more

October 12, 2018

Axicabtagene Ciloleucel Gets Japan’s Orphan Drug Designation to Treat Some Non-Hodgkin’s Lymphomas

News

The Japan Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug status to axicabtagene ciloleucel for the treatment of certain aggressive forms of non-Hodgkin’s lymphoma (NHL) namely diffuse large ... Read more

July 10, 2018

Lymphoma Therapies Kymriah, Yescarta Recommended for Approval in Europe

News

The European Medicines Agency (EMA) has recommended the approval of two lymphoma medications: Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). The EMA’s decision represents the first two recommendations for chimeric antigen receptors ... Read more

June 6, 2018

Phase 3 Trial to Test Yescarta as Second-line Therapy for DLBCL Patients

News

Kite Pharma has opened a new Phase 3 clinical trial to investigate the effectiveness of Yescarta (axicabtagene ciloleucel) as a second-line therapy for patients with relapsed or refractory diffuse large B-cell lymphoma ... Read more

January 19, 2018January 19, 2018

Phase 1/2 Trial to Test Yescarta-Utomilumab Combo in Refractory Large B-cell Lymphoma

News

A new multicenter Phase 1/2 trial will evaluate an immunotherapy combination of Yescarta (axicabtagene ciloleucel) and utomilumab for the treatment of patients with refractory large B-cell lymphoma. The trial, part of a clinical ... Read more

December 13, 2017

40% of Relapsed NHL Patients Remain Cancer-free a Year After Treatment with Kite’s Yescarta

News

More than a year after receiving the CAR T-cell therapy Yescarta (axicabtagene ciloleucel), 42 percent of the patients in the ZUMA-1 trial are still responding to the treatment, Kite Pharma announced. The Phase ... Read more